Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Yoshihara

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
Bone Marrow Transplantation|May 29, 2026
Comparative outcomes of umbilical cord blood transplantation versus haploidentical transplantation according to post-transplant cyclophosphamide use in adolescent and young adult patientsRyu Yanagisawa, Itaru Kato, Hiromi Hayashi, et al.
Blood Neoplasia|June 23, 2025
Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myelomaTomoyasu Jo, Kyoko Yoshihara, Masaki Ri, et al.
International Journal of Hematology|May 17, 2021
Expression of activated integrin β7 in multiple myeloma patientsNaoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, et al.
American Journal of Hematology|November 20, 2024
Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft typeTakaaki Konuma, Kazuaki Kameda, Kaoru Morita, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 15, 2004
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regressionYoshihiro Oka, Akihiro Tsuboi, Tetsuya Taguchi, et al.
Cancer Immunology, Immunotherapy : CII|May 17, 2024
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patientsYutaka Shimazu, Junya Kanda, Yoshiyuki Onda, et al.
European Journal of Haematology|January 21, 2021
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysisTeruhito Takakuwa, Ryosuke Yamamura, Kensuke Ohta, et al.
Therapeutic Advances in Hematology|July 5, 2022
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysisYoshiyuki Onda, Junya Kanda, Hitomi Kaneko, et al.
Annals of Hematology|March 16, 2024
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective studyNaokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, et al.
British Journal of Haematology|April 25, 2023
Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in JapanTomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
Bone Marrow Transplantation|May 29, 2026
Comparative outcomes of umbilical cord blood transplantation versus haploidentical transplantation according to post-transplant cyclophosphamide use in adolescent and young adult patientsRyu Yanagisawa, Itaru Kato, Hiromi Hayashi, et al.
Blood Neoplasia|June 23, 2025
Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myelomaTomoyasu Jo, Kyoko Yoshihara, Masaki Ri, et al.
International Journal of Hematology|May 17, 2021
Expression of activated integrin β7 in multiple myeloma patientsNaoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, et al.
American Journal of Hematology|November 20, 2024
Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft typeTakaaki Konuma, Kazuaki Kameda, Kaoru Morita, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 15, 2004
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regressionYoshihiro Oka, Akihiro Tsuboi, Tetsuya Taguchi, et al.
Cancer Immunology, Immunotherapy : CII|May 17, 2024
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patientsYutaka Shimazu, Junya Kanda, Yoshiyuki Onda, et al.
European Journal of Haematology|January 21, 2021
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysisTeruhito Takakuwa, Ryosuke Yamamura, Kensuke Ohta, et al.
Therapeutic Advances in Hematology|July 5, 2022
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysisYoshiyuki Onda, Junya Kanda, Hitomi Kaneko, et al.
Annals of Hematology|March 16, 2024
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective studyNaokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, et al.
British Journal of Haematology|April 25, 2023
Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in JapanTomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, et al.
Pageof 15